{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:33:01Z","timestamp":1776119581870,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/yco.0b013e328314b74b","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T10:28:31Z","timestamp":1223980111000},"page":"613-618","source":"Crossref","is-referenced-by-count":27,"title":["Addressing cardiometabolic risk during treatment with antipsychotic medications"],"prefix":"10.1097","volume":"21","author":[{"given":"Jonathan M","family":"Amiel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina V","family":"Mangurian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Ganguli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W","family":"Newcomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"R2-16-20210206","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R3-16-20210206","first-page":"1","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Prev Chronic Dis"},{"key":"R5-16-20210206","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.100.13.1481","article-title":"Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"key":"R6-16-20210206","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R7-16-20210206","first-page":"596","article-title":"Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"R8-16-20210206","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4088\/JCP.v69n0219","article-title":"Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of medicaid claims data","volume":"69","author":"Morrato","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"5 Suppl 1","key":"R9-16-20210206","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.jcp.0000142281.85207.d5","article-title":"The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists","volume":"24","author":"Newcomer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R10-16-20210206","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline","volume":"86","author":"Nasrallah","year":"2006","journal-title":"Schizophr Res"},{"key":"R11-16-20210206","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr Res"},{"key":"R12-16-20210206","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.4088\/JCP.v68n1006","article-title":"Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo","volume":"68","author":"L'Italien","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R13-16-20210206","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/10401230600801234","article-title":"Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies","volume":"18","author":"Ramaswamy","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"R14-16-20210206","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophr Res"},{"key":"R15-16-20210206","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2007.02.024","article-title":"Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis","volume":"93","author":"Strassnig","year":"2007","journal-title":"Schizophr Res"},{"key":"R16-16-20210206","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R18-16-20210206","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R19-16-20210206","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.genhosppsych.2007.05.001","article-title":"Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review","volume":"29","author":"Khazaal","year":"2007","journal-title":"Gen Hosp Psychiatry"},{"key":"R20-16-20210206","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1399-5618.2007.00488.x","article-title":"A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders","volume":"9","author":"McElroy","year":"2007","journal-title":"Bipolar Disord"},{"key":"R21-16-20210206","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study","volume":"165","author":"Wu","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R22-16-20210206","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","article-title":"Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial","volume":"93","author":"Baptista","year":"2007","journal-title":"Schizophr Res"},{"key":"R23-16-20210206","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.psychres.2008.01.011","article-title":"Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study","volume":"159","author":"Baptista","year":"2008","journal-title":"Psychiatry Res"},{"key":"R25-16-20210206","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R26-16-20210206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","article-title":"Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"key":"R27-16-20210206","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"R28-16-20210206","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.schres.2006.12.025","article-title":"Cognitive behavioural therapy for weight gain associated with antipsychotic drugs","volume":"91","author":"Khazaal","year":"2007","journal-title":"Schizophr Res"},{"key":"R29-16-20210206","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hup.707","article-title":"Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results","volume":"20","author":"Pendlebury","year":"2005","journal-title":"Hum Psychopharmacol"},{"key":"R30-16-20210206","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0447.2006.00906.x","article-title":"Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK","volume":"115","author":"Pendlebury","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"R31-16-20210206","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jada.2005.01.005","article-title":"Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication","volume":"105","author":"Sharpe","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"R33-16-20210206","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4088\/JCP.v67n0812","article-title":"Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial","volume":"67","author":"Alvarez-Jimenez","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R34-16-20210206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2006.01.008","article-title":"A cognitive\/behavioral group intervention for weight loss in patients treated with atypical antipsychotics","volume":"83","author":"Weber","year":"2006","journal-title":"Schizophr Res"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YCO.0b013e328314b74b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:43:33Z","timestamp":1620978213000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001504-200811000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e328314b74b","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}